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Abstract The phosphorylation of microtubule-associated pro-
teins (MAPs) is thought to be a key factor in the regulation of
microtubule (MT) stability. Previously we isolated DMAP-85, a
Drosophila MAP shown to be associated with stable MTs. In this
work we show that DMAP-85 phosphorylated in cell-free early
embryo extracts is released from MTs. MPM-2 antibodies
recognize the phosphorylated protein. In vitro, DMAP-85 can be
phosphorylated by the mitotic kinase Polo affecting its binding to
MTs and creating MPM-2 epitopes on the protein. The results
suggest that phosphorylation of DMAP-85 might affect its MT
stabilizing activity during early mitotic cycles. ß 2000 Feder-
ation of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
In living cells, microtubule (MT) dynamic is thought to be
modulated by a number of post-translational modi¢cations of
both tubulin and microtubule-associated proteins (MAPs).
MAPs bind to MTs in a nucleotide-independent way, promot-
ing MT assembly and stabilization [1^3]. Several lines of evi-
dence indicate that phosphorylation plays a major role in the
regulation of MAP activity. Most identi¢ed MAPs are regu-
lated by phosphorylation, and this modi¢cation interferes
with their MT stabilizing capabilities [4^8]. In neurons, phos-
phorylation of MAPs seems to modulate MT organization
during morphogenesis and process outgrowth [9,10]. In pro-
liferating cells, phosphorylation of MAPs is tightly coupled to
mitotic cycles and appears to regulate changes in MT dynamic
during the cell cycle [11].
Drosophila has emerged as an important experimental sys-
tem for the analysis of cytoskeletal functions [12,13]. The
studies on Drosophila MAPs have revealed the existence of
a MAP of 205 kDa, which colocalizes with interphase and
mitotic MTs [14]. Based on their ability to bind MT a⁄nity
columns, Kellogg et al. [15] identi¢ed several MAPs, some of
them have been cloned and their association to centrosomes
has been determined [16^19]. Recently, the gene products of
abnormal spindle (Asp) [20] and mini-spindle (Msp) [21] genes,
have been identify as MAPs, based on both their capacity to
bind MTs in vitro and molecular similarities with other
MAPs. Asp associates with centrosomes and, together with
the Q-tubulin ring complex, can restore MT nucleation activity
to salt-stripped centrosome preparations in vitro [22,23]. Msp
localizes to mitotic spindles and centrosomal regions during
mitosis and is required to maintain the integrity of the bipolar
spindle [21].
The e¡ects of phosphorylation upon the MT binding ca-
pacity of Drosophila MAPs have only been shown in vitro for
CP-60 [19]. Nevertheless, a strong genetic interaction has been
demonstrated between the mitotic Polo kinase and Asp sug-
gesting that the activity of Asp might be modi¢ed by this
kinase [24]. Polo is an essential protein kinase required for
multiple stages of mitosis. It has been shown to phosphorylate
the activator of p34cdc2 promoting entry into mitosis [25]. It
has also been shown to phosphorylate tubulin and at least two
MAPs in cell-free extracts [26]. More recently it has been
reported that Polo phosphorylates components of the ana-
phase promoting complex [27] and PAV-KLP, a kinesin-like
protein required for cytokinesis [28]. When phosphorylated by
Polo, a number of these proteins display reactivity to the
monoclonal antibody MPM-2 [29^31].
To explore further the regulatory activities of MAPs upon
MT behavior, we have isolated DMAP-85, a Drosophila 85
kDa MAP present in embryos, larvae and adults, as a protein
that can associate to taxol-stabilized MTs [32,33]. The bio-
chemical analyses of DMAP-85 indicated that this protein
cosediments with tubulin and promotes tubulin polymeriza-
tion in vitro through its interaction with exposed domains of
MTs, speci¢cally with MAPs binding sequences present at the
C-terminal end of L-tubulin [1,32,33]. These results suggest
that one of the functions of DMAP-85 could be to regulate
the dynamics of MT assembly in the cell.
In the work reported here, we have extended the biochem-
ical characterization of DMAP-85 and demonstrate that the
interaction of the protein with MTs in vitro is regulated by
phosphorylation. The MPM-2 antibody recognizes the
DMAP-85 phosphorylated in cell-free extracts. In vitro phos-
phorylation of DMAP-85 by Polo kinase causes its release
from MTs and creates MPM-2 epitopes on this protein. Our
data indicate that phosphorylation of DMAP-85 may be an
important regulatory mechanism for controlling the interac-
tion of this protein with MTs in vivo.
2. Materials and methods
2.1. Phosphorylation/dephosphorylation assays
High speed supernatant extracts were prepared from 200 Wl of 0^2 h
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embryos. Embryos were dechlorionated in 50% sodium hypochlorite
for 2^3 min, washed in HEM bu¡er (20 mM HEPES, pH 6.9, 1 mM
MgCl2, 1 mM EGTA), containing 0.1% Triton X-100, resuspended in
500 Wl of this solution plus protease inhibitors (1 Wg/ml leupeptin,
0.7 Wg/ml pepstatin, 1 Wg/ml aprotinin, 100 Wg/ml PMSF), and ho-
mogenized at 4‡C by several passes of a dounce tissue grinder. The
homogenates were clari¢ed by centrifugation at 12 000Ug and then
centrifuged at 50 000Ug for 20 min at 4‡C. Phosphorylation of native
DMAP-85 was assessed by adding 10U phosphatase inhibitor stock
(10 WM microcystin LR, 0.2 M NaF and 0.2 M L-glycerophosphate)
to 200 Wl of high speed supernatants, followed by 30 min incubation
at 22‡C, in the presence or in the absence of 1.0 Wl [32P]ATP. The
mixtures were diluted to 500 Wl with RIPA bu¡er (150 mM NaCl,
50 mM Tris^HCl, pH 8.0, 0.1% SDS, 0.5% sodium deoxycholate, 1%
NP-40) containing phosphatase inhibitors, and DMAP-85 was immu-
noprecipitated as described below. Immunocomplexes were resus-
pended in gel sample bu¡er and analyzed by SDS^PAGE followed
by Western blot (non-radioactive samples) or by Coomassie blue
staining and autoradiography (radioactive samples). Phosphorylated
proteins were cut out from stained dried gels and radioactivity was
measured by Cerenkov counting. For dephosphorylation assays, pro-
tein A beads with immunoprecipitated DMAP-85 were washed twice
with phosphatase bu¡er (50 mM Tris^HCl, pH 7.8, 5 mM DTT,
2 mM MnCl2, 100 Wg/ml BSA), resuspended in 25 Wl of the bu¡er
and incubated at 30‡C for 30 min with 270 U of Lambda phosphatase
(Calbiochem, San Diego, CA, USA). In order to phosphorylate re-
combinant DMAP-85, samples of high speed supernatants were di-
luted 0-, 5-, 15-, 25- and 35-fold in a preparation of puri¢ed recombi-
nant protein (0.4 mg/ml) and the phosphorylation assay was carried
out by adding to the mixture 10 Wl of 3U HEM bu¡er, 10U phos-
phatase inhibitor stock and 1.5 Wl [32P]ATP (10 mCi/ml). The mixture
was incubated 30 min at 20‡C and the reaction quenched by addition
of gel sample bu¡er and boiling. Proteins were analyzed by SDS^
PAGE and autoradiography.
2.2. Puri¢cation of recombinant protein
Escherichia coli cells JM109 containing pTrcHis-DMAP-85 vector
(Cambiazo et al., unpublished results) were cultured in LB medium
with 50 Wg/ml ampicillin at 37‡C. Expression of recombinant DMAP-
85 was induced by addition of IPTG to a ¢nal concentration of 1 mM
and the culture was further incubated at 37‡C for 3 h. The induced
cells were then harvested by centrifugation and soluble cell extracts
were prepared in lysis bu¡er from the Xpress System Protein Puri¢-
cation (Invitrogen Co., San Diego, CA, USA) with addition of pro-
tease inhibitors. DMAP-85 was puri¢ed using Probond columns (In-
vitrogen Co.). After elution, DMAP-85 enriched fractions were
concentrated by centrifugation in Ultrafree microcentrifuge ¢lters
(molecular mass cut-o¡: 30 000). Fractions were pooled, dialyzed
against HEM bu¡er overnight at 4‡C, and then clari¢ed by centrifu-
gation at 12 000Ug.
2.3. Immunoprecipitations
A⁄nity-puri¢ed anti-DMAP-85 antibody (10 Wg) was incubated 2 h
at 4‡C with 100 Wl of protein A beads (Sigma Chemical Co., St Louis,
MO, USA) diluted 1:10 in RIPA bu¡er, and the beads were washed
three times with 500 Wl of RIPA bu¡er. For Polo phosphorylation
assays, immunoprecipitated DMAP-85 was obtained as follows: cell-
free extracts were made from 0^2 h embryos (25‡C) in RIPA bu¡er,
using V0.1 g of embryos in 0.3 ml of bu¡er. After centrifugation of
the embryo homogenate at 12 000Ug, the supernatant, diluted 1:2 in
RIPA bu¡er and pre-cleared with 20 Wl of protein A beads 2 h at 4‡C,
was incubated overnight at 4‡C with anti-DMAP-85 antibody pre-
bound to protein A beads. The immunocomplexes were thoroughly
washed with RIPA bu¡er by pelleting at 100Ug and resuspending in
500 Wl of RIPA bu¡er ¢ve times. MPM-2 antibody reactive phospho-
proteins were immunoprecipitated from 0^2 h embryos as described
above; using 0.4 Wg/Wl anti-MPM-2 antibody (Upstate Biotechnology
Inc., Lake Placid, NY, USA) pre-bound to 50 Wl of protein G beads.
Depending on the experiment, phosphatase inhibitors were or were
not added to the RIPA bu¡er during immunoprecipitation assays.
Control immunoprecipitations were performed in parallel, in which
either protein A/G beads or antibodies were not included. Rabbit pre-
immune serum was also used as control in DMAP-85 immunopreci-
pitations. Proteins were resuspended in 50 Wl of gel sample bu¡er and
analyzed by SDS^PAGE and Western blot. Polo kinase was immu-
noprecipitated from 0^2 h embryos according to Tavares et al. [26]
except that 0.2 Wg/Wl anti-Polo antibody (MA294) pre-bound to 80 Wl
of protein G was added to 500 Wl of embryo extracts diluted 1:4 in
TM bu¡er (50 mM Tris^HCl, pH 7.4, 5 mM MgSO4, 1 mM Na3VO4,
0.5 M NaF) that contained 0.5% NP-40 and 1 WM microcystin LR
[31]. The immunocomplexes were washed ¢ve times in TM bu¡er, and
immediately used in phosphorylation assays.
2.4. Assays for MT binding activity
Tubulin was puri¢ed from bovine brains by three cycles of temper-
ature-dependent assembly^disassembly followed by P-11 phosphocel-
lulose chromatography [34]. High speed supernatants from 0^2 h
(300 Wl) embryos were incubated for 15 min at 37‡C with or without
1 WM microcystin LR, before the addition of 20 WM taxol (Sigma
Chemical Co.), 1 mM GTP and 0.3 mg/ml brain tubulin. In other
experiments, 100 Wl of tubulin (1.0 mg/ml) was admixed with phos-
phorylated or unphosphorylated recombinant protein diluted to 90 Wl
with HEM bu¡er, and assembly was initiated by the addition of 1 mM
GTP and 20 WM taxol to the assay mixture (0.25 ml ¢nal volume). In
both cases, after 30 min incubation at 37‡C, the mixtures were layered
over 100 Wl of 15% sucrose in HEM bu¡er plus 20 WM taxol and
centrifuged at 125 000Ug for 30 min at 20‡C. The pellets were washed
twice with HEM bu¡er plus 20 WM taxol and resuspended in gel
sample bu¡er. Equivalent fractions of supernatants and pellets were
analyzed by SDS^PAGE and Western blot.
2.5. Polo kinase assays
Protein A beads with immunoprecipitated DMAP-85 and protein G
beads with immunoprecipitated Polo kinase were rinsed twice in ki-
nase bu¡er (20 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA,
2 mM DTT, 1 WM microcystin LR, 20 mM NaF, 1 mM Na3VO4 and
20 mM L-glycerophosphate). Polo and DMAP-85 beads were mixed,
pelleted and resuspended in 30 Wl of kinase bu¡er containing 1 mM
ATP and 1.0 Wl [32P]ATP (10 mCi/ml). In control experiments, de-
phosphorylated casein (2.0 Wl of a 1 mg/ml solution) was used as a
substrate of Polo kinase. In some experiments, Polo beads were mixed
with 7.5 Wl of recombinant DMAP-85 (0.9 mg/ml), in the presence or
absence of [32P]ATP for 20 min at 20‡C. The ¢nal volume of the
mixtures was 30 Wl. Phosphorylated proteins were or were not tested
for binding to MTs, and then analyzed by SDS^PAGE followed by
Western blot or by autoradiography. For Polo immunodepletion, cell-
free extracts were made from 0^2 h embryos in HEM bu¡er contain-
ing 0.5% NP-40 and protease inhibitors and incubated for 2 h at 4‡C
in the absence or presence of 0.2 Wg/Wl anti-Polo antibody. Extracts
were incubated with protein G beads for 1 h at 4‡C. Supernatants
were saved and the incubation repeated overnight with or without the
anti-Polo antibody, followed by 1 h incubation with protein G beads.
Supernatants were diluted to 5 Wg/Wl in HEM bu¡er (0.5 ml ¢nal
volume) containing 0.5 mM ATP, 1 mM DTT phosphatase and pro-
tease inhibitors. They were incubated for 20 min at 20‡C and DMAP-
85 was immunoprecipitated from the extracts using an anti-DMAP-85
antibody pre-bound to protein A beads as described above. Immuno-
precipitated proteins were analyzed by SDS^PAGE and Western blot.
2.6. Gel electrophoresis, immunoblotting and autoradiography
SDS^PAGE was performed according to the method of Laemmli
[35], with 10% or 15% acrylamide gels. For immunoblotting, gels were
transferred to nitrocellulose membranes according to standard proce-
dure [36]. Blots were processed as described in Cambiazo et al. [37].
Bound antibodies were revealed using DAB Liquid substrate System
(Sigma Chemical Co.) or ECL reagents (Amersham Corp, Arlington
Heights, IL, USA). Anti-DMAP-85 antibody [33] was used at 1:500,
anti-MPM-2 antibody was diluted 1:10 000. For autoradiography,
gels were dried and exposed to X-OMAT AR ¢lms (Kodak) at
370‡C.
3. Results
A direct interaction of DMAP-85 with MTs has been pre-
viously characterized [32,33]. In this work we test whether
DMAP-85 is phosphorylated and whether binding to MTs is
a¡ected by the phosphorylation state of the protein. To de-
termine if DMAP-85 is phosphorylated, the protein was im-
munoprecipitated from 0^2 h embryo extracts, in the presence
FEBS 24185 6-10-00
V. Cambiazo et al./FEBS Letters 483 (2000) 37^4238
of phosphatase inhibitors, and its electrophoretic mobility an-
alyzed after treatment with Lambda phosphatase. The results
indicate that phosphatase treatment causes a shift in the elec-
trophoretic mobility of DMAP-85 (Fig. 1, lanes 1 and 2). To
con¢rm that the change in mobility is due to phosphorylation,
the extract was incubated with [Q-32P]ATP, followed by im-
munoprecipitation with anti-DMAP-85 speci¢c antibodies
(Fig. 1, lane 3). However, if the pellet is treated with Lambda
phosphatase the radioactive label is removed (Fig. 1, lane 4).
The results show that under these conditions DMAP-85 in-
corporates 32P from [Q-32P]ATP, with a stoichiometry of
6.2 þ 2.3 mol/mol protein (n = 3).
The ability of MAPs to bind MTs has been shown to be
a¡ected by its phosphorylation state. Therefore, we investi-
gated the e¡ect of the phosphatase inhibitor microcystin LR
on the capacity of DMAP-85 to bind MTs in crude extracts
from 0^2 h embryos. A high speed supernatant from embryo
extracts was incubated with taxol and bovine brain tubulin in
the absence or in the presence of microcystin LR. The binding
of DMAP-85 to taxol MTs was assayed by centrifugation and
analysis of supernatants and pellets by SDS^PAGE and Coo-
massie blue staining (Fig. 2A) or Western blot (Fig. 2B). Fig.
2A shows that the pattern of protein sedimentation with MTs
is not broadly a¡ected by the addition of microcystin LR. In
the absence of microcystin LR, a signi¢cant fraction of
DMAP-85 cosediments with MTs (Fig. 2B, lanes 1 and 2).
In the presence of 1 WM microcystin LR, a concentration
su⁄cient to inhibit both type 1 and 2A phosphatases, a negli-
gible amount of DMAP-85 binds to MTs and appears in the
pellet (Figs. 2B, 3 and 4). These results indicate that DMAP-
85 is a substrate for phosphorylation by a kinase activity
present in the embryo high speed supernatant. Also, a phos-
phatase activity present in the extracts appears to modulate
the MT binding of native DMAP-85, so that the protein only
binds MTs when dephosphorylated.
To correlate the ability of DMAP-85 to bind MTs with its
phosphorylation state, we used recombinant DMAP-85 as a
source of unmodi¢ed protein. Incubation of this protein with
[Q-32P]ATP in the presence of a low protein concentration of
high speed supernatant (dilution 1:35) results in its phosphor-
ylation (Fig. 3A, lane 1), while the phosphorylation of endog-
enous DMAP-85 is hardly detectable (Fig. 3A, lane 2). In the
control reaction, absence of diluted supernatant, there is no
Fig. 1. Phosphorylation of DMAP-85. DMAP-85 was immunopreci-
pitated from 0^2 h embryo extracts in the absence (lanes 1 and 2)
or in the presence of [Q-32P]ATP (lanes 3 and 4), and either left un-
treated (lanes 1 and 3), or treated with Lambda phosphatase (lanes
2 and 4). Samples were then analyzed by SDS^PAGE and the gels
were transferred to nitrocellulose membranes and probed with an
anti-DMAP-85 antibody (lanes 1 and 2), or dried and exposed for
autoradiography (lanes 3 and 4).
Fig. 2. E¡ects of microcystin LR on MT binding of DMAP-85 in
cell-free extracts. Cell-free extracts from 0^2 h embryos were incu-
bated without (3Mc) or with (+Mc) 1 WM microcystin LR for
15 min at 37‡C, before the addition of 20 WM taxol and 0.3 mg/ml
tubulin. After 30 min incubation at 37‡C and centrifugation, pellet
(lanes 1 and 3) and supernatant (lanes 2 and 4) samples were ana-
lyzed by SDS^PAGE followed by Coomassie blue staining (A) or
by immunoblotting with a polyclonal antibody anti-DMAP-85 (B).
Fig. 3. In vitro phosphorylation of recombinant DMAP-85 in the
presence of endogenous kinases and interaction with MTs. A: Cell-
free extract from 0^2 h embryos diluted 1:35 in a preparation of re-
combinant DMAP-85 (lane 1), cell-free extract diluted 1:35 in HEM
bu¡er (lane 2) or recombinant DMAP-85 (lane 3) were incubated
with [Q-32P]ATP at 20‡C for 30 min. Samples were analyzed by
means of SDS^PAGE and autoradiography. B: Recombinant
DMAP-85 (7.5 Wg) was phosphorylated with endogenous kinases
from embryo extracts and tested for binding to MTs. Supernatants
(S) and pellets (P) were analyzed by SDS^PAGE, transferred to ni-
trocellulose and probed with an antibody against DMAP-85. Phos-
phorylated recombinant protein fails to cosediment with MTs (lanes
1 and 2), while unphosphorylated protein is found in the pellet frac-
tion (lanes 3 and 4). C: In the absence of MTs, both phosphorylat-
ed (lanes 1 and 2) and unphosphorylated (lanes 3 and 4) proteins
remain in the supernatant fractions. (rDMAP-85 = recombinant
DMAP-85.)
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incorporation of 32P into DMAP-85 (Fig. 3A, lane 3). Once
the conditions for phosphorylation of the recombinant
DMAP-85 were established we tested whether the phosphor-
ylation of the protein a¡ects its ability to bind MTs in a
cosedimentation assay. The results show that when recombi-
nant DMAP-85 is incubated with the extract under conditions
that favor its phosphorylation, V100% of protein remains in
the supernatant (Fig. 3B, lanes 1 and 2). However, the un-
phosphorylated recombinant DMAP-85 cosediments with tu-
bulin and is recovered in the pellet fraction after centrifuga-
tion (Fig. 3B, lanes 3 and 4). In the absence of MTs both
phosphorylated (Fig. 3C, lanes 1 and 2) and unphosphory-
lated proteins (Fig. 3C, lanes 3 and 4) are found in the super-
natant fractions. These results suggest that the state of phos-
phorylation of both recombinant and native DMAP-85 is
directly related to their ability to bind MTs.
In proliferating cells or tissues a similar e¡ect has been
described for several other MAPs. In the case of MAP-4, it
has been reported that phosphorylation by p34cdc2 creates an
MPM-2 reactive epitope that correlates with its e¡ect on MT
stability [38,39]. The MPM-2 monoclonal antibody has been
shown to recognize a subset of proteins that become phos-
phorylated during the transition from interphase to mitosis
[40^43]. Accordingly, we proceed to test whether the phos-
phorylation of DMAP-85 is associated with MPM-2 reactiv-
ity. For this we immunoprecipitated DMAP-85 from embryo
extracts in the presence or absence of microcystin LR (Fig. 4).
The immunoprecipitates were separated by SDS^PAGE, blot-
ted to nitrocellulose and then probed with an MPM-2 anti-
body. The results (Fig. 4A) show that a speci¢c anti-DMAP-
85 antibody can immunoprecipitate an MPM-2 reactive pro-
tein in the presence of the phosphatase inhibitor, but not in its
absence (Fig. 4A, lanes 2 and 3). In order to con¢rm these
results, we have carried out the converse experiment by im-
munoprecipitating with the MPM-2 speci¢c antibody and
probing with the anti-DMAP-85 antibody. As shown in Fig.
4B, a fraction of DMAP-85 speci¢cally immunoprecipitates
with MPM-2 antibody, in the presence but not in the absence
of microcystin LR. These results indicate that when phosphor-
ylated, DMAP-85 is an MPM-2 reactive phosphoprotein.
A number of protein kinases have been shown to be respon-
sible for the phosphorylation of MPM-2 reactive epitopes
[42,44,45]. Among them, the Polo mitotic kinase is particu-
larly important since its phosphorylation of CDC25 leads to
activation of p34cdc2 and entry into mitosis [25]. Furthermore,
for the purpose of our study, previous work showed that the
Drosophila Polo kinase speci¢cally phosphorylated an 85 kDa
protein in embryo extracts [26]. Thus, we tested whether Polo
is able to phosphorylate DMAP-85 in vitro (Fig. 5A). For
this, we ¢rst immunoprecipitated Polo from embryo extracts
in the presence of phosphatase inhibitors and tested its kinase
activity against casein. The data (Fig. 5A, lane 1) show that
under these conditions Polo is immunoprecipitated as an ac-
tive kinase. We then immunoprecipitated DMAP-85 from em-
bryo extracts in the absence of phosphatase inhibitors and use
it as a substrate for a phosphorylation reaction with immu-
noprecipitated Polo. The result shows that DMAP-85 is phos-
phorylated by the active Polo kinase (Fig. 5A, lane 2). This
reaction is speci¢c since it is not observed in the absence of
immunoprecipitated DMAP-85 (lane 3), when pre-immune
serum was used (lane 4) or in the absence of Polo (lane 5).
These results indicate that Polo phosphorylates DMAP-85 in
vitro. In order to investigate whether Polo is involved in the
creation of MPM-2 epitopes on DMAP-85, this protein was
immunoprecipitated from Polo-immunodepleted extracts, in
the presence of phosphatase inhibitors and probed with the
MPM-2 antibody. Whereas incubation of extracts with pro-
tein G beads has no e¡ect on the formation of MPM-2 epi-
topes (Fig. 5B, lane 2), immunodepletion of Polo kinase from
the extract results in a loss of the MPM-2 reactivity of im-
munoprecipitated DMAP-85 (Fig. 5B, lane 3). These results
strongly suggest that DMAP-85 phosphorylation by Polo ki-
nase generates MPM-2 epitopes on this protein.
Our results show that phosphorylation of DMAP-85 a¡ects
its ability to bind MTs and also that Polo can speci¢cally
phosphorylate the protein in vitro. Therefore we assessed
whether phosphorylation by Polo can modify the binding of
DMAP-85 to MTs. Unphosphorylated or Polo phosphorylat-
ed recombinant DMAP-85 was incubated with puri¢ed MTs
and its binding ascertained by a sedimentation assay (Fig.
5C). Western blots of supernatant and pellet fractions indicate
that unphosphorylated recombinant protein cosediments with
MTs (Fig. 5C, lanes 1 and 2). However, when the recombi-
nant protein is phosphorylated by Polo, approximately 40%
of the protein does not associate to MTs and remains in the
supernatant (Fig. 5C, lanes 3 and 4). In order to know
whether the protein fraction bound to MTs was phosphory-
lated, we added [Q-32P]ATP to the Polo phosphorylation assay
and used the 32P-labeled protein in the sedimentation proce-
dure. Our data from Fig. 5D show that unbound protein has
incorporated 32P from [Q-32P]ATP (Fig. 5D, lane 1), while the
fraction of DMAP-85 that cosediments with MTs (Fig. 5D,
Fig. 4. MPM-2 reactivity of phosphorylated DMAP-85. A: Cell-free
extracts from 0^2 h embryos were prepared in the presence (+Mc)
or in the absence (3Mc) of 1 WM microcystin LR and incubated
with pre-immune serum (lane 1) or anti-DMAP-85 antibody (lanes
2 and 3). Immunoprecipitated proteins were analyzed by Western
blots, using a monoclonal anti-MPM-2 antibody. B: Cell-free ex-
tracts prepared in the presence (+Mc) or in the absence (3Mc) of
microcystin LR were incubated with an anti-MPM-2 antibody. Both
fractions, immunoprecipitates (I) and supernatants (S) were analyzed
by SDS^PAGE, transferred to nitrocellulose and probed with the
anti-DMAP-85 antibody. A fraction of DMAP-85 immunoprecipi-
tates with the anti-MPM-2 antibody in the presence (lanes 3 and 4)
but not in the absence (lanes 1 and 2) of microcystin LR. Arrows
indicate DMAP-85 position.
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lane 2), remains unphosphorylated. These results indicate that
Polo phosphorylation a¡ect the MT binding ability of
DMAP-85.
4. Discussion
In previous reports we have shown that DMAP-85 stabil-
izes MTs, promotes MT assembly [32] and associates to stable
MTs in late Drosophila embryos [1]. In this report we examine
the post-translational modi¢cations of this protein during de-
velopmental stages known to be characterized by rapid mi-
totic divisions. Our in vitro studies suggest that DMAP-85 is
phosphorylated by the Polo mitotic kinase, and that this mod-
i¢cation alters its MT binding capacity.
We ¢rst show that when DMAP-85 is puri¢ed from early
embryo extracts (0^2 h), it displays an altered pattern of elec-
trophoretic mobility that is correlated with the protein being
phosphorylated. Furthermore, in this cell-free system we ¢nd
that the binding of DMAP-85 to MTs can be regulated by the
presence or the absence of phosphatase inhibitors, which are
known to alter the equilibrium between phosphorylated and
dephosphorylated proteins. Reversible phosphorylation of
MAPs is well established as a mechanism for the rapid regu-
lation of MT rearrangements through the activity of many
kinases modulated by extracellular factors. In fact, activation
of cellular phosphorylation mechanisms, after treatments with
phosphatase inhibitors, has been shown to modify MT dy-
namics in vitro [46] and in vivo [47,48].
In order to study the e¡ects of phosphorylation of DMAP-
85 upon its ability to bind MTs, we have produced a recombi-
nant protein and phosphorylate it by endogenous kinases in a
cell-free assay. We showed that the phosphorylated protein is
unable to bind to MTs, suggesting that the activity of this
protein is regulated in vivo by phosphorylation. Accordingly,
we propose that the MT stabilizing activity of DMAP-85 is
abolished during early stages of embryonic development when
most of the MTs are highly dynamic polymers, characterized
by the absence of any tubulin modi¢cations associated with
stable MTs [49,50]. Similar results have been obtained for
other MAPs, including XMAP-4 [8], p220 [4,51] MAP-4 [5],
EMAP-115 [52], CP-60 [19] and EMAP [53]. The phosphory-
lation of these MAPs correlates with the transition from in-
terphase to mitosis, and it has been associated with the acti-
vation of the general mitotic kinases, such as p34cdc2 [11]. It
has been proposed that this modi¢cation alters the MT stabi-
lizing capacity of these MAPs [54].
In proliferating cells the transition from interphase to mi-
tosis has been shown to be associated with the phosphoryla-
tion of a large group of proteins. A subset of these proteins is
recognized due to their reactivity with the MPM-2 monoclo-
nal antibody [40^43]. At least one MAP has been reported to
be an MPM-2 reactive phosphoprotein in vitro [38,39]. Our
results show that the mitotic phosphorylation of DMAP-85
creates MPM-2 reactive epitopes in this protein. Thus, these
results suggest that the presence of MPM-2 reactive epitopes
is not only correlated with the activation of mitotic proteins
but can also result in the inactivation of proteins that promote
MT stabilization.
A number of protein kinases are known to phosphorylate
mitotic substrates thereby creating MPM-2 reactive phospho-
epitopes [29,30,44,45,55]. One of these kinases corresponds to
Polo kinase, which has been shown to bind a number of
compartments of the mitotic apparatus [31], and it is required
throughout mitotic progression [56,57]. Our data indicate that
DMAP-85 is phosphorylated in vitro by Polo kinase and that
this phosphorylation generates MPM-2 epitopes on the pro-
tein. In our hands, the maximum extent of DMAP-85 Polo-
dependent phosphorylation was 40% with respect to the total
DMAP-85 present in the assays. This result is in good agree-
ment with the fraction of recombinant DMAP-85 that be-
comes unable to bind to MT after Polo phosphorylation,
and indicates that phosphorylation mediated by Polo kinase
regulates the binding of DMAP-85 to MTs. Considering that
Polo phosphorylates DMAP-85 in vitro, and that MPM-2
reactivity of DMAP-85 is dependent on endogenous Polo ki-
nase activity, we propose that Polo might be responsible for
the phosphorylation of DMAP-85 during early stages of em-
bryogenesis, a¡ecting its MT binding activity, and thus mod-
ulating the MT stabilizing capacity of DMAP-85.
Polo activity is essential for the G2/M transition [56,57],
and it has been associated with direct phosphorylation of
tubulin [26]. Furthermore, it has been shown that in the ab-
sence of Polo, spindle MTs are more resistant to depolymer-
ization by colchicine and display a morphology resembling
taxol treated MTs [58]. Therefore, it has been proposed that
Polo might be required to promote an increase in MT dynam-
Fig. 5. In vitro phosphorylation of DMAP-85 by Polo kinase. A:
The autoradiographs show the phosphorylation of casein (lane 1)
and immunoprecipitated DMAP-85 (lane 2) by immunoprecipitated
Polo kinase. In control experiments, anti-DMAP-85 or anti-Polo
antibodies were omitted (lanes 3 and 5) and immunoprecipitation
assays were carried out in the presence of pre-immune serum (lane
4). B: DMAP-85 was immunoprecipitated from 0^2 h embryo ex-
tract in the presence of phosphatase inhibitors followed by Western
blot analysis with an anti-MPM-2 monoclonal antibody (lane 1).
Pre-incubation of the extracts with protein G beads had little e¡ect
on the formation of MPM-2 epitopes (lane 2). In contrast, immuno-
depletion of Polo kinase results in a loss of the MPM-2 reactivity
of DMAP-85 (lane 3). C: Recombinant DMAP-85 (6.7 Wg) was
phosphorylated with immunoprecipitated Polo kinase and assayed
for binding to MTs. Supernatants (S) and pellets (P) were analyzed
by SDS^PAGE, transferred to nitrocellulose and probed with an
anti-DMAP-85 antibody. The immunoblot indicates that unphos-
phorylated recombinant protein cosediments with MTs (lanes 1 and
2) while approximately 40% of Polo phosphorylated protein is
found in the supernatant fraction (lanes 3 and 4). D: Recombinant
DMAP-85 was incubated with immunoprecipitated Polo in the pres-
ence of 1 mM [Q-32P]ATP at 20‡C for 30 min, and tested for bind-
ing to MTs. The autoradiograph indicates that phosphorylated pro-
tein fails to cosediment with MTs. Supernatant (lane 1) and pellet
(lane 2).
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ics associated with entry into mitosis [58]. Our results show
that the phosphorylation of DMAP-85 by Polo a¡ects its MT
binding properties. Therefore, we suggest that Polo might
alter MT dynamics through the phosphorylation of MT sta-
bilizing proteins like DMAP-85.
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